Open Access

Evaluation of therapeutic effects of 125I particles brachytherapy for recurrent bladder cancer

  • Authors:
    • Yu-Ming Zhou
    • Xiao Feng
    • Bing-Cheng Zhou
    • Yue-Feng Fan
    • Yuan-Liang Huang
  • View Affiliations

  • Published online on: December 29, 2017     https://doi.org/10.3892/ol.2017.7723
  • Pages: 3453-3457
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the clinical value of 125I particles implantation in the treatment of recurrent bladder cancer. The study is a retrospective analysis of 32 patients with recurrent bladder cancer treated between May 2010 and January 2010. Of these, 16 cases (chemotherapy group) received conventional chemotherapy. A total of 16 patients (125I group) received radiotherapy with 125I particles, followed by conventional chemotherapy. By guidance of B ultrasound, 125I radioactive particles were implanted. All 32 patients were relieved after treatment, and the tumors were significantly reduced after 2 months. However, the tumors in the 125I group were significantly smaller than those in the chemotherapy group (P<0.05). The patients were followed‑up for 1 year and no recurrence was found. Additionally, no complications occurred. Compared with the chemotherapy group, the tumor volume of the 125I group was significantly reduced (P<0.05). The disease-free survival and 5-year survival rates of the patients in the follow-up showed that the disease-free survival and 5-year survival rates of the patients in 125I group were significantly improved compared to those in the chemotherapy group. Therefore, the results have shown that 125I radioactive particles in the treatment of bladder cancer improve the symptoms of patients with bladder cancer in the short term, and continuously kill residual tumor and prevent recurrence.

Introduction

125I particles are capable of releasing X-ray and gamma-rays in the process of decay, through in vivo implantation for continuous internal radiation therapy. These particles have the ability to inhibit tumor cell proliferation and induce apoptosis. 125I has a low dose rate, high relative biological effect, appropriate radius of killing, and is used widely in the treatment of a variety of malignant tumors, showing obvious advantages in the local control and survival rate of patients (1,2). With the rapid development of molecular biology, modern advanced biology techniques have been used to study the mechanism of tumorigenesis and prognosis, and the treatment of malignant tumors with 125I particles is no exception. Through a lot of basic research, the molecular mechanism of 125I particles in radiotherapy for malignant tumor has achieved certain results in the induction of tumor cell apoptosis and cell cycle arrest, intracellular signal transduction and inhibition of tumor angiogenesis. In patients with recurrent bladder cancer, the efficacy of the general chemotherapy regimen is limited (3). In this study, we implanted 125I radioactive particles into the tumor, and observed the clinical efficacy of this treatment modality during recurrent bladder cancer.

Materials and methods

General

A total of 16 patients with recurrent bladder cancer treated with 125I, there were 13 males and 3 females, aged 47–69 years, and the average was 59.2±3.28 years. Of the 16 cases, 10 cases were diagnosed as transitional cell carcinoma, 1 case was squamous cell carcinoma, and 5 cases were hamartoma. All 16 patients had hematuria, urinary frequency and urgency symptoms, and 1 patient had dysuria. In the chemotherapy group, there were 14 males and 2 females, aged 43–65 years, with an average age of 58.3±2.33 years. Of these, 8 cases were transitional cell carcinoma, 4 cases were squamous cell carcinoma, and 4 cases were hamartoma. All 16 patients had hematuria, urinary frequency and urgency symptoms. There was no significant difference in age between the two groups. There was no significant difference in pathological types and the number of complications by the Chi-square test (P>0.05) (Table I).

Table I.

Comparison of general clinical data.

Table I.

Comparison of general clinical data.

VariablesNo. of casesSex (male/female)Age (years)Transitional cell carcinomaSquamous cell carcinomaHamartoma
125I group1613/359.2±3.281015
Chemotherapy group1614/258.3±2.33  844
T/χ2 value0.430.220.83
P-value0.590.780.18

The present study has been approved by the Ethics Committee of The First Affiliated Hospital of Xiamen University (Fujian, China). Informed consents were signed by the patients and/or guardians.

Instruments

The instruments used for the study were: 3D-stereotactic radiotherapy planning system for tumor tissue (TPS, jointly designed and developed by the China Institute of Atomic Energy and Beijing Bo Intel System Engineering Co., Ltd., Beijing, China). Plant equipments included planting needles, planting guns, templates and B ultrasonic. The radioactive 125I particle source was obtained from the American SynQor Inc. (Boxborough, MA, USA), and the activity of each particle was 0.40–0.50 mCi, with a half-life of 60.1 days; gamma-ray energy of 27,35 kEV; and tissue penetration distance of 1.7 cm.

Methods

To determine the range of tumor surface markers measured by B ultrasound, combined with the TPS planning system, the grid was drawn using the pitch 1.0 cm square matrix. Each intersection of the grid served as the access channel. After local routine disinfection, an ultrasonic probe navigation frame was fixed to the edge of the tumor. From this point, the needle was taken up to 1 cm from the edge of the tumor, the first particle was planted, and the needle was withdrawn 1 cm. The second particle was planted, up to 1 cm from the edge of the tumor, the last particle of the channel was planted, and the replacement of the channel continued to grow. A postoperative indwelling catheter was left, with regular bladder irrigation, antibiotics were taken to prevent infection, and hemostasis and other symptomatic treatments were taken. Tumor sites and the number of implants of 125I group are presented in Table II.

Table II.

Tumor location and number of implanted particles.

Table II.

Tumor location and number of implanted particles.

No.AgeTumor locationTumor size (cm3)No. of particles
  158Right anterior wall of bladder21.240
  257Right posterior wall of bladder  9.220
  354Right anterior wall of bladder  9.820
  459Right anterior wall of bladder  4.8  9
  553Left posterior wall of bladder10.220
  650Left posterior wall of bladder11.320
  749Posterior wall and right wall of bladder20.340
  863Right anterior wall of bladder12.520
  952Right posterior wall of bladder  3.8  9
1053Right anterior wall of bladder   4.4  9
1154Posterior wall and right wall of bladder   5.4  9
1259Posterior wall and right wall of bladder   5.7  9
1361Right wall of bladder   7.810
1460Left and right posterior wall of bladder   9.820
1558Right posterior wall of bladder   9.620
1669Posterior wall and right wall of bladder   3.5  9
Chemotherapy regimen

Both groups of patients were treated with internal iliac artery chemotherapy for the first time within 2 weeks after surgery, and the second internal iliac artery chemotherapy was performed within 1 month after surgery in the two groups. The chemotherapeutic drugs Pharmorubcin 30 mg/m2 (surface area) was taken each time. The Seldinger technique was used to puncture one side of the femoral artery, and internal iliac artery angiography was taken on both sides to observe the blood supply of the bladder. The catheter was placed into the internal iliac artery of the affected side, and 2/3 of the drug was injected. Then the catheter was placed into the contralateral internal iliac artery, and the remaining 1/3 of the drug was injected. Following chemotherapy, hydration, alkalization and hepatoprotective treatments were taken.

Curative effect judgment

According to the improvement of clinical symptoms, the changes of tumor size by the re-examination of B-ultrasound or CT and CT review after 17 months, the curative effect was evaluated.

Statistical analysis

The collected data were processed using SPSS 15.0 statistical software (SPSS, Inc., Chicago, IL, USA). Measurement data were presented as mean ± SD. An independent sample t-test was used for comparison between groups. Countable data were expressed by case number or constituent ratio, and tested using the Chi-square test. The log-rank test and COX multivariate analysis were used to analyze the prognosis of the patients. A P<0.05 was considered to indicate a statistically significant analysis.

Results

Changes of tumor volume before and after treatment

We analyzed the tumor volume of the two groups before and after treatment by CT. The results showed that the tumor volume of the two groups of patients after treatment was significantly reduced. The tumor volume of 125I was 9.33±5.27 before treatment, while it reduced to 3.44±1.23 after treatment. The tumor volume of patient in chemotherapy group was 9.21±1.23 before treatment and 6.57±2.17 after treatment. However, compared with the chemotherapy group, the tumor volume of the 125I group was significantly reduced (P<0.05) (Table III).

Table III.

Changes of tumor volume before and after treatment.

Table III.

Changes of tumor volume before and after treatment.

VariablesNumber of casesBefore treatmentAfter treatmentT-valueP-value
125I group169.33±5.273.44±1.232.180.02
Chemotherapy group169.21±1.236.57±2.173.280.012
T-value0.273.49
P-value0.790.003
Comparison of survival prognosis

Concerning the survival prognosis of the two groups, we found that compared with the chemotherapy group, the 125I group had a significantly higher survival rate of five years (P<0.05). Disease-free survival was significantly prolonged (P<0.05). The difference was statistically significant (P<0.05) (Figs. 1 and 2).

Discussion

Bladder cancer is one of the most common malignant tumors in the urinary system. The key to treatment is to control the recurrence and metastasis of the local tumor through multidisciplinary efforts (46). For nearly half a century, the academic community has made noteworthy progress in the comprehensive treatment of surgery, radiotherapy and chemotherapy. However, the recurrence rate within a few years after tumor resection is 50–80% and invasive evolution accounts for 50–80% in recurrent cases (7). Although radical cystectomy is widely accepted, there is currently no evidence that surgery is more effective than radiotherapy. Furthermore, radiotherapy may retain the bladder, especially in improving the quality of life of patients as it has greater advantages (8). Although there are certain effects of external radiotherapy, the loss of normal tissue is serious and the quality of life is also reduced. Moreover, it has side effects and high equipment costs.

Brachytherapy was performed by implanting radioactive sources into the hollow organs (intracavitary radiotherapy) or directly implanted in the tumor tissue (interstitial brachytherapy). A short range of treatment ranging from approximately 5 mm to 5 cm characterizes it. Additionally, the radiation dose is mainly concentrated in a small part of the tumor tissue and surrounding normal tissue (9). High-dose irradiation can be obtained in the treatment of brachytherapy and the surrounding normal tissues may be well protected (10). Brachytherapy is one of main treatments of bladder cancer and prostate cancer (11). The physical half-life of the radioactive element 125I particles is 59.6 days, with the energy of 27.4–31.5 Kev X-rays and 35.5 Kev gamma-rays (12). When the 125I particles were implanted into the tumor focus and the lymphatic system, the particles were scattered with low energy X-rays and gamma-rays. Tumor proliferation was significantly reduced by continuous irradiation (13). At the same time, continuous low energy irradiation inhibits tumor mitosis, with the tumor cell concentration in the G2 phase, resulting in tumor cell killing by radiation effect to the maximum, to effectively inhibit tumor cell proliferation and cytothesis, in order to achieve the purpose of cure (14). Furthermore, 125I particles are not involved in metabolism, and cause little damage to the patients and medical staff (15). In particular, according to the intraoperative situation, targeted at a certain location, tumor cells are directly killed at different stages of the cell cycle (16). However, conventional external irradiation is short-time high-intensity fractionated irradiation, which could kill the M cells. This is often terminated because the patient could not tolerate the radiation reaction (17). Interstitial implantation of radioactive 125I particles brachytherapy is a minimally invasive treatment technology developed in previous years, showing a good therapeutic effect in the clinical practice of treating multiple cancers with high efficiency and few side effects (18).

Brachytherapy is primarily used for the treatment of bladder and prostate cancer (19). However, to the best of our knowledge, there is no report on the application of 125I particles implantation in the treatment of bladder cancer (20). Our results have shown that 125I particles were implanted into the lesion or in the tissue for the treatment of bladder cancer, and the local recurrence rate was low. At the same time, the unresectable cancer tissue or the remaining tissue was directly radiated (21). Our study found that tumor volume measurement and statistical analysis in the CT of the two groups of patients before and after treatment were significantly reduced as compared with prior to treatment. However, compared with the chemotherapy group, the tumor volume of 125I group was significantly reduced. Following a comparison of the survival prognosis of the two groups, we found that compared with the chemotherapy group, the 125I group had a significantly higher survival rate of 5 years (P<0.05). Disease-free survival was significantly prolonged (P<0.05). The results showed that 125I particle radiation therapy has good clinical efficacy in clinical life therapy and survival prognosis of recurrent bladder cancer patients.

125I particle implantation-assisted radiotherapy for the treatment of bladder cancer is optimal compared to in vitro irradiation treatment, and especially applicable to patients for whom surgery is not possible. 125I particles are capable of killing the tumor cells directly, and are not affected by the oxygen content in tumor cells (22,23). Owing to the accurate localization, the local effective dose is large, but the radiation distance is small, the radiation damage is slight, and there is no obvious adverse effect on the surrounding tissue. Therefore, the side effects are small and have no significant influence on the quality of life (24). We believe that the treatment of bladder cancer by 125I particles brachytherapy is more advantageous than that of in vitro irradiation. It has the following advantages (2529): i) The radioactive source is small, the half-life is short (only 60 days), the energy is low, and the killing radius is not more than 2 cm; ii) the operation is simple, the 125I particle source may be implanted into the tissue under direct vision, the accuracy of the treatment is improved, and the range of the surgical injury is reduced; iii) the accuracy rate of the cancer tissue is high, and the continuous emission of pure gamma-ray can effectively hit the mitotic phase of the cancer cell. The continuous low-dose irradiation inhibits the mitosis of the tumor cells, and the curative effect is good; and iv) it may effectively improve the dose distribution ratio of tumor and normal tissue.

In conclusion, we believe that 125I radioactive particles in the treatment of bladder cancer may not only improve the symptoms of patients with bladder cancer in the short term, rapidly reduce the tumor, but also continuously kill residual tumor and prevent recurrence of the tumor.

References

1 

Ohga S, Nakamura K, Shioyama Y, Tatsugami K, Sasaki T, Nonoshita T, Yoshitake T, Asai K, Hirata H, Naito S and Honda H: Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer. J Radiat Res. 55:1178–83. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Martens C, Pond G, Webster D, McLean M, Gillan C and Crook J: Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy. 5:9–13. 2006. View Article : Google Scholar : PubMed/NCBI

3 

Arias F, Dueñas M, Martínez E, Domínguez MA, Illarramendi JJ, Villafranca E, Tejedor M, Molina F, Meiriño R and Valerdi JJ: Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle. Cancer. 80:115–120. 1997. View Article : Google Scholar : PubMed/NCBI

4 

Li Y, Lin K, Yang Z, Han N, Quan X, Guo X and Li C: Bladder cancer stem cells: Clonal origin and therapeutic perspectives. Oncotarget. 8:66668–66679. 2017.PubMed/NCBI

5 

Radford IR and Aldridge DR: Importance of DNA damage in the induction of apoptosis by ionizing radiation: Effect of the scid mutationand DNA ploidy on the radiosensifivity of murine lymphoid cell lines. Int J Radiat Biol. 75:143–153. 1999. View Article : Google Scholar : PubMed/NCBI

6 

Ohga S, Nakamura K, Shioyama Y, Tatsugami K, Sasaki T, Nonoshita T, Yoshitake T, Asai K, Hirata H, et al: Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer. J Radiat Res. 55:1178–1183. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Prada PJ, Hevia M, Juan G, Abascal JM, de la Rúa A, Abascal R, Fernández J and Rodríguez R: I125 Low dose rate brachytherapy in localized prostate cancer. Preliminary results after 5 years. Arch Esp Urol. 58:213–226. 2005.(In Spanish). PubMed/NCBI

8 

Lucerna M, Pomyje J, Mechtcheriakova D, Kadl A, Gruber F, Bilban M, Sobanov Y, Schabbauer G, Breuss J, Wagner O, et al: Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res. 66:6708–6713. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Nowak AK, Chow PKH and Findlay M: Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer. 40:1474–1484. 2004. View Article : Google Scholar : PubMed/NCBI

10 

Wang Y, Ji P, Liu J, Broaddus RR, Xue F and Zhang W: Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer. 8:82009. View Article : Google Scholar : PubMed/NCBI

11 

Cao XF, He XT, Ji L, Xiao J and Lv J: Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus. 22:477–481. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Wu MY, Wu XY, Li QS and Zheng RM: Expression of Egr-1 gene and its correlation with the oncogene proteins in non-irradiated and irradiated esophageal squamous cell carcinoma. Dis Esophagus. 19:267–272. 2006. View Article : Google Scholar : PubMed/NCBI

13 

Gassmann M, Chilov D and Wenger RH: Regulation of the hypoxia-inducible factor-1 alpha. ARNT is not necessary for hypoxic induction of HIF-1 alpha in the nucleus. Adv Exp Med Biol. 475:87–99. 2000. View Article : Google Scholar : PubMed/NCBI

14 

Sjöström A, Bue P, Malmstrom P and Carlsson J: Binding of 125I after administration of 125I-EGF-dextran, 125I-EGF or 125I to human bladder cancer spheroids. Int J Oncol. 17:559–564. 2000.PubMed/NCBI

15 

Sjöström A, Bue P, Malmström PU, Nilsson S and Carlsson J: Binding, internalization and degradation of EGF-dextran conjugates in two human bladder-cancer cell lines. Int J Cancer. 70:383–389. 1997. View Article : Google Scholar : PubMed/NCBI

16 

Mariani G, Collecchi P, Baldassarri S, Di Luca L, Buralli S, Fontanini G, Baranowska-Kortylewicz J, Adelstein SJ and Kassis AI: Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2′- deoxyuridine after intravesical infusion in patients with bladder cancer. J Nucl Med. 37:16–19. 1996.PubMed/NCBI

17 

van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ and Kassis AI: Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med. 37:315–320. 1996.PubMed/NCBI

18 

Colpi GM, Fanciullacci F, Beretta G, Negri L and Zanollo A: Evoked sacral potentials in subjects with true premature ejaculation. Andrologia. 18:583–586. 1986. View Article : Google Scholar : PubMed/NCBI

19 

Xin ZC, Choi YD, Rha KH and Choi HK: Somatosensory evoked potentials in patients with primary premature ejaculation. J Urol. 158:451–455. 1997. View Article : Google Scholar : PubMed/NCBI

20 

Xin ZC, Chung WS, Choi YD, Seong DH, Choi YJ and Choi HK: Penile sensitivity in patients with primary premature ejaculation. J Urol. 156:979–981. 1996. View Article : Google Scholar : PubMed/NCBI

21 

Smith K, Fennelly JA, Neal DE, Hall RR and Harris AL: Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res. 49:5810–5815. 1989.PubMed/NCBI

22 

Tamura K, Araki F and Ohno T: SU-F-T-46: The effect of inter-seed attenuation and tissue composition in prostate 125I brachytherapy dose calculations. Med Phys. 43:3471–3472. 2016. View Article : Google Scholar

23 

Tan Q, Qin Q, Yang W, Lian B, Mo Q and Wei C: Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study. Medicine (Baltimore). 95:e53022016. View Article : Google Scholar : PubMed/NCBI

24 

Jeon J, Shim HE, Mushtaq S, Choi MH, Park SH, Choi DS and Jang BS: An optimized protocol for the efficient radiolabeling of gold nanoparticles by using a 125I-labeled azide prosthetic group. J Vis Exp. e547592016.

25 

Jiao D, Wu G, Ren J and Han X: Radiofrequency ablation versus 125I-seed brachytherapy for painful metastases involving the bone. Oncotarget. 7:87523–87531. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Becker S, Schlederer T, Kramer MF, Haack M, Vrtala S, Resch Y, Lupinek C, Valenta R and Gröger M: Real-life study for the diagnosis of house dust mite allergy - the value of recombinant allergen-based IgE serology. Int Arch Allergy Immunol. 170:132–137. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Sheikholeslami S, Nedaie HA, Sadeghi M, Pourbeigy H, Shahzadi S, Zehtabian M, Hasani M and Meigooni AS: Monte Carlo calculations and experimental measurements of the TG-43U1-recommended dosimetric parameters of 125I (Model IR-Seed2) brachytherapy source. J Appl Clin Med Phys. 17:430–441. 2016. View Article : Google Scholar : PubMed/NCBI

28 

Asadi S, Vaez-Zadeh M, Vahidian M, Marghchouei M and Masoudi SF: Ocular brachytherapy dosimetry for 103Pd and 125I in the presence of gold nanoparticles: A Monte Carlo study. J Appl Clin Med Phys. 17:90–99. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Sugawara A1, Nakashima J, Shigematsu N, Kunieda E and Kubo A: Prediction of seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds. Brachytherapy. 8:52–56. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou Y, Feng X, Zhou B, Fan Y and Huang Y: Evaluation of therapeutic effects of 125I particles brachytherapy for recurrent bladder cancer. Oncol Lett 15: 3453-3457, 2018
APA
Zhou, Y., Feng, X., Zhou, B., Fan, Y., & Huang, Y. (2018). Evaluation of therapeutic effects of 125I particles brachytherapy for recurrent bladder cancer. Oncology Letters, 15, 3453-3457. https://doi.org/10.3892/ol.2017.7723
MLA
Zhou, Y., Feng, X., Zhou, B., Fan, Y., Huang, Y."Evaluation of therapeutic effects of 125I particles brachytherapy for recurrent bladder cancer". Oncology Letters 15.3 (2018): 3453-3457.
Chicago
Zhou, Y., Feng, X., Zhou, B., Fan, Y., Huang, Y."Evaluation of therapeutic effects of 125I particles brachytherapy for recurrent bladder cancer". Oncology Letters 15, no. 3 (2018): 3453-3457. https://doi.org/10.3892/ol.2017.7723